norovirus
member
famili
calicivirida
noroviru
infect
global
health
burden
impact
million
individu
annual
us
alon
norovirus
associ
high
morbid
among
vulner
popul
particularli
immunocompromis
patient
perspect
highlight
recent
develop
relat
discoveri
develop
norovirusspecif
smallmolecul
therapeut
well
recent
advanc
understand
noroviru
biolog
pathogenesi
work
area
earli
discoveri
stage
primarili
focus
inhibitor
noroviru
proteas
rna
depend
rna
polymeras
howev
recent
discoveri
eman
basic
studi
noroviru
research
result
identif
new
hostrel
drug
target
exploit
repurpos
compound
advanc
human
clinic
studi
introduct
assess
ongo
research
futur
direct
area
special
emphasi
discoveri
smallmolecul
noroviru
therapeut
phylogenet
analysi
major
viral
capsid
gene
serv
basi
classifi
norovirus
six
genogroup
givi
human
norovirus
caus
gastroenter
belong
three
distinct
genogroup
gi
gii
giv
subdivid
genotyp
virus
gii
genogroup
preval
strain
primarili
respons
infect
outbreak
acut
gastroenter
mutat
recombin
account
high
degre
genet
antigen
divers
found
norovirus
consequ
emerg
new
strain
result
sporad
outbreak
epidem
worldwid
caliciviru
genom
organ
polyprotein
process
calicivirus
small
nonenvelop
virus
possess
singlestrand
sens
genom
rna
kb
coval
link
viral
protein
vpg
virion
protein
genomelink
end
polyadenyl
end
figur
genom
consist
three
open
read
frame
encod
kda
polyprotein
major
capsid
protein
contain
antigen
cell
bind
determin
respect
compris
shell
domain
protrud
p
domain
subdivid
two
subdomain
mani
function
associ
hypervari
region
includ
interact
individu
oligosaccharid
residu
histoblood
group
antigen
hbga
receptor
sialic
acidcontain
glycosphingolipid
encod
small
basic
protein
believ
enhanc
stabil
structur
integr
matur
polyprotein
process
virusencod
cystein
proteas
gener
six
nonstructur
protein
ntpaserna
helicas
vpg
proteas
rnadepend
rna
polymeras
rdrp
figur
coand
posttransl
process
polyprotein
noroviru
essenti
viru
replic
function
fulli
elucid
howev
kda
vpg
protein
coval
link
genom
subgenom
mrna
coval
linkag
end
noroviru
rna
essenti
viru
infect
noroviru
chymotrypsinlik
cystein
proteas
activ
site
compris
prototyp
catalyt
triad
locat
interfac
domain
domain
noroviru
induc
fit
enzym
extend
bind
cleft
like
strand
rna
virus
replic
viral
genom
effect
viral
encod
rdrp
genom
subgenom
rna
synthesi
viral
rdrp
entail
two
differ
mechan
de
novoiniti
mechan
vpgdepend
mechan
central
role
play
rdrp
viru
replic
render
attract
target
develop
norovirusspecif
antivir
human
norovirus
enter
pathogen
etiolog
associ
gastroenter
human
age
group
noroviru
infect
complex
diseas
involv
interplay
multipl
host
viral
factor
mediat
includ
varianc
genet
suscept
noroviru
infect
aris
differ
bind
affin
noroviru
strain
blood
antigen
experiment
condit
human
norovirus
infect
primat
pig
cattl
pig
cattl
infect
human
norovirus
replic
virus
found
enterocyt
develop
mild
moder
diarrhea
primat
human
viru
infect
lead
fecal
viru
shed
without
clear
clinic
symptom
earli
biopsi
result
norovirusinfect
human
suggest
noroviru
infect
may
induc
histopatholog
chang
villu
stunt
may
result
malabsorpt
diarrhea
howev
limit
histopatholog
chang
intestin
tract
observ
exclud
possibl
norovirus
may
infect
cell
enterocyt
contribut
norovir
diarrhea
vomit
via
less
known
mechan
immunocompromis
patient
noroviru
infect
lead
persist
gastroenter
diarrhea
recent
find
relat
noroviru
infect
includ
disrupt
human
mous
gut
microbiota
persist
infect
associ
commens
microb
infect
dendrit
cell
macrophag
b
cell
evas
immun
system
via
continu
viral
evolut
role
host
cell
factor
illumin
mani
aspect
diseas
studi
laid
groundwork
formul
model
norovirus
infect
intestin
briefli
involv
bind
norovirus
carbohydr
receptor
express
enterocyt
follow
transcytosi
across
intestin
epithelium
infect
macrophag
dendrit
cell
b
cell
howev
signific
advanc
made
area
research
remain
need
better
definit
molecular
mechan
underli
norovirusinduc
diarrhea
besid
support
fluid
therapi
treatment
option
avail
individu
suffer
acut
gastroenter
current
limit
norovirusspecif
antivir
agent
yet
approv
fda
thu
avail
efficaci
safe
noroviru
therapeut
prophylact
antivir
would
major
impact
control
noroviru
infect
principl
viral
host
factor
serv
potenti
target
antivir
drug
discoveri
furthermor
step
viral
replic
cycl
target
figur
advent
robust
highli
sensit
fretbas
assay
noroviru
cellbas
replicon
system
greatli
facilit
identif
evalu
antinoroviru
hit
gener
true
virus
antivir
aim
target
viral
compon
attach
entri
uncoat
inhibitor
well
proteas
polymeras
inhibitor
noroviru
may
result
select
resist
mutant
unwant
side
effect
inhibit
host
factor
involv
bodili
function
concern
antivir
target
host
factor
either
case
nontox
noroviru
therapeut
rapidli
reduc
viral
load
effect
prophylact
would
constitut
major
advanc
field
noroviru
attract
target
discoveri
develop
norovirusspecif
therapeut
vital
role
proteas
play
viral
life
cycl
figur
effort
focus
abet
avail
sever
highresolut
xray
crystal
structur
enzym
without
bound
ligand
figur
xray
crystal
structur
complex
inhibitor
provid
detail
map
activ
site
exploit
structurebas
design
potent
inhibitor
structur
proteas
solut
determin
use
highfield
nmr
figur
enzym
predominantli
monom
solut
xray
crystal
structur
noroviru
show
enzym
exist
dimer
interestingli
flexibl
backbon
loop
appear
play
import
role
substrat
recognit
substrat
specif
relev
determin
substrat
specif
enzym
ascertain
use
array
tool
includ
vitro
transcript
translat
structur
studi
use
chromogen
fluorogen
substrat
tabl
compar
purpos
substrat
specif
proteas
relat
virus
also
includ
tabl
similar
activ
site
topographi
noroviru
picornaviru
coronaviru
proteas
suggest
fashion
broadspectrum
antivir
agent
principl
feasibl
mechan
action
similar
establish
relat
cystein
proteas
act
nucleophil
function
gener
acidbas
facilit
align
promot
deproton
oxyanion
tetrahedr
intermedi
stabil
presenc
oxyanion
hole
adjac
activ
site
aforement
structur
biochem
studi
place
design
optim
inhibitor
secur
structur
biochem
foot
made
possibl
use
structurebas
approach
discoveri
antinoroviru
therapeut
principl
gener
design
strategi
employ
construct
transit
state
ts
inhibitor
ts
mimic
exampl
involv
link
peptidyl
recognit
element
x
correspond
known
substrat
specif
target
enzym
appropri
warhead
moieti
resembl
transit
state
enzymat
reaction
case
ts
mimic
figur
recognit
element
typic
span
two
subsit
serv
dock
posit
inhibitor
correctli
activ
site
via
network
hydrogen
bond
backbon
inhibitor
activ
site
residu
figur
thu
format
initi
enzymeinhibitor
noncoval
complex
within
proteas
activ
site
follow
reaction
activ
site
cystein
warhead
lead
revers
format
stabl
tetrahedr
adduct
figur
common
warhead
employ
includ
aldehyd
nitril
moieti
exampl
ts
mimic
includ
unlik
inhibitor
incorpor
warhead
structur
interact
ts
mimic
enzym
involv
noncoval
bind
interact
exampl
chart
repres
highli
effect
noroviru
inhibitor
illustr
approach
importantli
compound
shown
vivo
efficaci
mnv
mous
model
tripeptidyl
inhibitor
also
effect
howev
increas
polar
surfac
area
result
diminish
cellular
permeabl
rupintrivir
chart
enteroviru
proteas
inhibitor
incorpor
structur
michael
acceptor
interact
via
michael
addit
reaction
also
display
antinoroviru
activ
chemic
reactiv
warhead
employ
design
ts
inhibitor
occasion
associ
lack
select
consequ
offtarget
effect
may
result
unaccept
toxic
necessit
investig
optim
select
attain
use
mask
warhead
exampl
bisulfit
adduct
capabl
revert
precursor
carbonyl
physiolog
condit
highli
advantag
figur
pharmacolog
activ
bisulfit
adduct
peptidyl
aldehyd
shown
parallel
parent
aldehyd
compound
chart
illustr
use
approach
gener
use
peptidederiv
drug
associ
sever
disadvantag
includ
high
conform
flexibl
suscept
proteolyt
degrad
poor
membran
permeabl
low
oral
bioavail
shortcom
frequent
mitig
depeptit
effect
way
depeptit
linear
peptid
macrocycl
preorgan
structur
rigid
character
macrocycl
peptid
frequent
enhanc
pharmacolog
activ
reduc
entrop
penalti
associ
bind
furthermor
increas
proteolyt
stabil
effect
macrocycl
cellular
permeabl
oral
bioavail
less
predict
howev
paramet
augment
macrocycl
engag
intramolecular
hydrogen
bond
basi
aforement
consider
peptidyl
ts
inhibitor
depeptid
tether
p
gln
residu
p
residu
side
chain
linear
peptid
use
appropri
linker
yield
macrocycl
scaffold
figur
addit
design
consider
relat
macrocycl
includ
ensur
ring
size
macrocycl
would
optim
term
allow
macrocycl
assum
conform
structur
motif
recogn
proteas
paramount
import
conform
would
allow
proper
dockingposit
inhibitor
activ
site
turn
would
orient
correctli
side
chain
p
p
residu
therebi
maxim
hydrogen
bond
hydrophob
bind
interact
inde
macrocycl
compound
found
potent
permeabl
inhibitor
tabl
unpublish
data
inhibit
viral
rna
depend
rna
polymeras
highli
success
endeavor
result
introduct
sever
rdrp
inhibitor
clinic
central
role
play
noroviru
rdrp
viru
replic
lack
human
homologu
render
rdrp
attract
target
antivir
drug
discoveri
sever
xray
crystal
structur
human
murin
noroviru
rdrp
wellsuit
serv
launch
pad
design
rdrp
inhibitor
report
includ
complex
ribavirin
suraminrel
compound
figur
rdrp
inhibitor
report
thu
far
list
chart
high
throughput
screen
led
identif
low
micromolar
nonnucleosid
inhibitor
rdrp
compound
chart
importantli
shown
rdrp
inhibitor
effect
norovirusinduc
diarrhea
mortal
murin
model
noroviru
infect
favipiravir
also
shown
inhibit
noroviru
replic
vitro
futur
develop
relat
rdrp
inhibitor
like
identifi
addit
promis
nucleosid
nonnucleosid
direct
act
antivir
flurri
activ
relat
design
discoveri
inhibitor
noroviru
attach
entri
andor
uncoat
hbgabind
site
conserv
human
norovirus
molecul
block
hbga
bind
site
potenti
therapeut
valu
screen
carbohydr
librari
small
molecul
librari
result
identif
multipl
bind
blocker
recent
demonstr
endosom
cystein
proteas
cathepsin
l
requir
caliciviru
replic
offer
anoth
promis
avenu
investig
identifi
molecul
potenti
therapeut
valu
despit
impress
progress
understand
noroviru
life
cycl
need
sharper
definit
viru
exploit
host
factor
surviv
propag
infect
mention
earlier
multipl
host
cell
factor
includ
network
host
protein
interact
end
human
murin
noroviru
genom
play
critic
role
viral
rna
replic
moreov
studi
shown
cholesterol
pathway
well
molecular
chaperon
compon
ribonucleoprotein
complex
could
also
serv
potenti
target
novel
therapeut
option
inhibitor
chart
well
repurpos
inhibitor
other
provid
intrigu
possibl
noroviru
drug
discoveri
lastli
deubiquitinas
inhibitor
respect
provid
anoth
promis
avenu
develop
noroviru
therapeut
chart
array
molecul
antinoroviru
activ
includ
cyclic
acycl
sulfamid
piperazin
pyranobenzopyron
deriv
well
relat
compound
discov
scaffold
hop
report
howev
mechan
action
remain
elucid
chart
case
cyclic
acycl
sulfamid
found
moder
inhibit
mnv
furthermor
resist
viru
select
serial
passag
unpublish
data
nitazoxanid
antiprotozo
prodrug
use
treatment
infecti
diarrhea
caus
cryptospiridium
parvum
giardia
lamblia
demonstr
efficaci
noroviru
infect
clinic
trial
limit
inform
antinorovir
effect
mechan
action
nitazoxanid
provid
strong
valid
drug
repurpos
mean
identifi
compound
inhibit
noroviru
specif
antivir
therapi
prophylaxi
current
exist
noroviru
infect
increas
realiz
noroviru
infect
repres
signific
health
burden
worldwid
exact
heavi
toll
among
elderli
young
immunocompromis
popul
provid
impetu
behind
effort
relat
discoveri
noroviru
therapeut
prophylact
vaccin
effort
abet
advanc
basic
scienc
underli
biolog
pathophysiolog
diseas
although
targetbas
approach
drug
discoveri
area
focus
viral
target
primarili
noroviru
rna
depend
rna
polymeras
identif
increas
number
host
factor
potenti
target
like
continu
integr
part
drug
discoveri
process
drug
target
valid
drug
target
select
base
rel
wellestablish
criteria
consequ
new
molecular
target
need
valid
recent
studi
noroviru
result
identif
lead
compound
highli
effect
multipl
human
noroviru
genotyp
well
murin
noroviru
demonstr
proof
concept
mnv
anim
model
inhibitor
wellsuit
conduct
preclin
studi
ultim
lead
identif
clinic
candid
much
ongo
work
area
irrespect
molecular
target
earli
stage
drug
discoveri
nevertheless
prospect
eventu
introduct
noroviru
therapeut
clinic
would
appear
excel
human
noroviru
life
cycl
potenti
therapeut
intervent
site
site
attach
entri
uncoat
respect
site
proteas
rdrp
inhibitor
respect
site
virion
assembl
inhibitor
norwalk
viru
show
two
domain
activ
site
catalyt
residu
locat
interfac
two
domain
b
ribbon
represent
solut
structur
nv
catalyt
residu
shown
stick
short
strand
shown
green
color
c
connolli
surfac
precursor
aldehyd
inhibitor
bound
nv
proteas
neighbor
residu
color
yellow
nonpolar
white
weakli
polar
cyan
polar
p
residu
cyclohexyl
alanin
side
chain
nestl
hydrophob
pocket
hydrogen
bond
interact
nv
precursor
aldehyd
deriv
compound
crystal
condit
use
bisulfit
adduct
revert
back
aldehyd
inhibitor
interact
form
enzymeinhibitor
complex
backbon
hydrogen
bond
facilit
proper
bind
posit
inhibitor
activ
site
carbonyl
oxygen
glutamin
surrog
form
two
hydrogen
bond
gener
represent
revers
interact
transit
state
inhibitor
cystein
proteas
oxyanion
tetrahedr
intermedi
locat
oxyanion
hole
b
depict
mechan
inhibit
cystein
proteas
bisulfit
adduct
deriv
transit
state
inhibitor
case
aldehyd
equilibrium
bisulfit
adduct
precursor
aldehyd
phdepend
kim
gener
design
macrocycl
inhibitor
tether
side
chain
gln
residu
suitabl
linker
primari
substrat
specif
nv
requir
invari
gln
glu
kim
noroviru
rna
depend
rna
polymeras
pdb
code
structur
compris
palm
blue
thumb
green
finger
red
domain
author
manuscript
kim
et
al
tabl
macrocycl
inhibitor
noroviru
proteas
